Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 14, 2017. The report disseminates a press release from ViiV Healthcare, a global specialist HIV company majority-owned by GSK (with Pfizer Inc. and Shionogi Limited as shareholders). The filing details positive Phase III clinical trial results for an investigational two-drug HIV regimen.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a clinical update rather than a financial earnings report.
Material Changes and Clinical Results
The primary material update concerns the SWORD 1 and SWORD 2 Phase III studies evaluating a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen) for HIV-1 maintenance therapy in virologically suppressed patients.
- Efficacy: The two-drug regimen demonstrated non-inferior viral suppression (HIV-1 RNA <50 copies/mL) at 48 weeks compared to standard three- or four-drug regimens. In pooled analysis, suppression rates were 95% for the investigational arm (486/513) and 95% for the control arm (485/511).
- Failure Rates: Virologic failure rates were <1% in the dolutegravir/rilpivirine arm and 1% in the control arm. No integrase strand transfer inhibitor (INSTI) resistance-associated mutations were reported.
- Safety: The most common adverse events (>5%) in the investigational arm were nasopharyngitis, headache, diarrhea, and upper respiratory tract infection. Serious adverse event rates were comparable between groups (27 vs. 21), though more patients withdrew due to adverse events in the investigational arm (21 vs. 3).
Guidance, Outlook, and Management Commentary
John C. Pottage, Jr., MD, Chief Scientific and Medical Officer at ViiV Healthcare, stated that the data challenges the 20-year standard that three or more drugs are required for HIV suppression. Management views these results as a significant step toward making two-drug regimens a reality.
- Regulatory Outlook: ViiV Healthcare plans to submit regulatory filings for the two-drug regimen as a single tablet in 2017.
- Current Status: The use of this specific two-drug combination is investigational and not approved anywhere in the world as of the filing date.
- Study Continuation: The studies are ongoing for a total duration of 148 weeks.
Investor Verification Checklist
- Verify the timeline for regulatory submissions for the dolutegravir/rilpivirine single tablet in 2017.
- Monitor the 148-week study data for long-term safety and efficacy beyond the 48-week mark.
- Assess the commercial impact of a potential two-drug regimen on the existing HIV portfolio and competitive landscape.
- Review the specific withdrawal rates due to adverse events to understand tolerability risks compared to standard care.
- Confirm the partnership status and revenue-sharing terms between ViiV Healthcare, GSK, Pfizer, and Janssen regarding this specific combination.